1986
DOI: 10.1001/archopht.1986.01050200132067
|View full text |Cite
|
Sign up to set email alerts
|

Oral Colchicine for the Treatment of Experimental Traction Retinal Detachment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
22
0
2

Year Published

1986
1986
2014
2014

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 73 publications
(24 citation statements)
references
References 25 publications
0
22
0
2
Order By: Relevance
“…This dose was chosen because there is little published data regarding the lethal dose of colchicine in rabbits, and this dose was well tolerated in an unrelated study. 5 The study rabbits receiving triamcinolone received a single 4-mL injection of 10-mg/mL triamcinolone infiltrated subcutaneously in the area of envenomation, 2 hours after envenomation. The study rabbits receiving diphenhydramine received a 10-mg/kg subcutaneous injection twice daily for 7 days.…”
Section: Methodsmentioning
confidence: 99%
“…This dose was chosen because there is little published data regarding the lethal dose of colchicine in rabbits, and this dose was well tolerated in an unrelated study. 5 The study rabbits receiving triamcinolone received a single 4-mL injection of 10-mg/mL triamcinolone infiltrated subcutaneously in the area of envenomation, 2 hours after envenomation. The study rabbits receiving diphenhydramine received a 10-mg/kg subcutaneous injection twice daily for 7 days.…”
Section: Methodsmentioning
confidence: 99%
“…These data suggest that a prophylactic, post-surgical intravitreal injection of a cocktail of antibodies targeted against CTGF, HGF, and PDGF may help reduce the recurrence of PVR. A treatment strategy that targets these growth factors, or their receptors, may be more beneficial in inhibiting PVR development, than nonspecific antiproliferative agents, such as heparin, 36 daunorubicin, 37 5-fluorouracil (5-FU), 38 colchicine, 39 taxol, 40 radiation 41 or a ribozyme technology targeted to proliferating cell nuclear antigen (PCNA). 42 …”
Section: Colocalization Of Pdgf With Rpe and Glial In Pvr Membranementioning
confidence: 99%
“…49 Laboratory and clinical studies suggest that pharmacological adjuvant therapy can modify the proliferative disease process and improve the success of surgery. There are a number of studies showing a potential benefit of a variety of pharmacological interventions including: retinoic acid, 7-17,50,51 dexamethasone, [11][12][13]52,53 colchicine, 14,15,54 taxol 16,17,55 and daunorubicin. 18,19,56 However, none of these regimens are in routine clinical use.…”
Section: Adjuvant Therapy For the Treatment Of Pvrmentioning
confidence: 99%